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Treatment of individuals with cystic fibrosis (CF) has been transformed by small molecule
therapies that target select pathogenic variants in the CF transmembrane conductance
regulator (CFTR). To expand treatment eligibility, we stably expressed 43 rare missense
CFTR variants associated with moderate CF from a single site in the genome of human CF
bronchial epithelial (CFBE41o–) cells. The magnitude of drug response was highly
correlated with residual CFTR function for the potentiator ivacaftor, the corrector lumacaftor,
and ivacaftor-lumacaftor combination therapy. Response of a second set of 16 variants
expressed stably in Fischer rat thyroid (FRT) cells showed nearly identical correlations.
Subsets of variants were identified that demonstrated statistically significantly higher
responses to specific treatments. Furthermore, nearly all variants studied in CFBE cells (40
of 43) and FRT cells (13 of 16) demonstrated greater response to ivacaftor-lumacaftor
combination therapy than either modulator alone. Together, these variants represent 87% of
individuals in the CFTR2 database with at least 1 missense variant. Thus, our results
indicate that most individuals with CF carrying missense variants are (a) likely to respond
modestly to currently available modulator therapy, while a small fraction will have
pronounced responses, and (b) likely to derive the greatest benefit from combination
therapy.
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Introduction
Targeting specific mutant forms of  defective cystic fibrosis transmembrane conductance regulator (CFTR) 
with orally bioavailable modulators has revolutionized treatment of  CF (1–4). Ivacaftor, the first drug to 
achieve US Food and Drug Administration (FDA) approval, potentiates function by altering chloride channel 
gating and increasing the open probability (Po) of  CFTR (5–7). Ivacaftor was originally approved for indi-
viduals with CF who carried at least 1 copy of  the p.Gly551Asp (G551D) variant. Subsequent clinical trials 
demonstrated benefit for individuals with CF who carried at least 1 copy of  any 1 of  8 variants that affected 
the gating of  CFTR (8, 9). The second drug, lumacaftor, was developed to correct protein folding defects 
caused by the most common CF-causing variant, p.Phe508del (F508del) (10, 11). While lumacaftor alone 
was not clinically effective for individuals homozygous for F508del (12), coadministration of  lumacaftor 
and ivacaftor improved clinical outcome measures for individuals homozygous for F508del (13). Recently, 
tezacaftor, a second corrector compound, demonstrated clinical efficacy in F508del homozygotes when com-
bined with ivacaftor (14). The same combination of  CFTR-targeted drugs also proved efficacious in a clinical 
trial of  individuals with CF who carried F508del in trans with a select set of  residual function variants (15).
Ivacaftor alone or in combination with either lumacaftor or tezacaftor has demonstrated efficacy for 39 
of  the approximately 1,640 CFTR variants associated with CF (http://www.CFTR2.org). This leaves thou-
sands of  individuals with CF who carry variants that have not been approved or in many cases even exper-
imentally tested for response to these 3 drugs. Review of  the untested variants indicates that approximately 
50% are predicted to generate CFTR protein and, therefore, could potentially be targeted with the currently 
available drugs (3). Unfortunately, clinical trials of  uncommon variants are difficult to conduct due to the 
wide geographic dispersion of  the small number of  individuals carrying these variants. Moreover, the high 
Treatment of individuals with cystic fibrosis (CF) has been transformed by small molecule therapies 
that target select pathogenic variants in the CF transmembrane conductance regulator (CFTR). To 
expand treatment eligibility, we stably expressed 43 rare missense CFTR variants associated with 
moderate CF from a single site in the genome of human CF bronchial epithelial (CFBE41o–) cells. The 
magnitude of drug response was highly correlated with residual CFTR function for the potentiator 
ivacaftor, the corrector lumacaftor, and ivacaftor-lumacaftor combination therapy. Response of a 
second set of 16 variants expressed stably in Fischer rat thyroid (FRT) cells showed nearly identical 
correlations. Subsets of variants were identified that demonstrated statistically significantly higher 
responses to specific treatments. Furthermore, nearly all variants studied in CFBE cells (40 of 43) 
and FRT cells (13 of 16) demonstrated greater response to ivacaftor-lumacaftor combination therapy 
than either modulator alone. Together, these variants represent 87% of individuals in the CFTR2 
database with at least 1 missense variant. Thus, our results indicate that most individuals with 
CF carrying missense variants are (a) likely to respond modestly to currently available modulator 
therapy, while a small fraction will have pronounced responses, and (b) likely to derive the greatest 
benefit from combination therapy.
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cost of  CFTR modulators has made off-label prescription problematic. Even if  an individual with a rare 
variant responds well in the clinic, insurers may not support the cost of  treatment unless the modulator is 
FDA approved for that particular genotype. Thus, alternative approaches are needed to assess the response 
to CFTR modulators for rare variants. Cell-based functional assays represent an avenue for evaluating rare 
variants in cases where clinical studies or assessment of  primary tissues are impractical, provided these sys-
tems are well vetted and generate reproducible results. Fischer rat thyroid (FRT) cells have been extensively 
used as a model cell line for studying the role of  CFTR in epithelial ion transport (16, 17), and FRT cell 
lines expressing CFTR cDNA have been used in a number of  studies to generate response data that have 
provided preliminary evidence to proceed to clinical trials (5, 10, 18, 19) and, more recently, to facilitate 
drug label expansion (20). CF bronchial epithelial cell line CFBE41o– (herein referred to as CFBE) cells 
provide an opportunity to test the effects of  CFTR variants in a human cell line from a relevant tissue type 
with a transcriptome that is very similar to that of  primary airway epithelial cells (21). These 2 cell lines 
offer complementary platforms to evaluate the functional consequences and responses to modulators of  
CFTR missense variants in a standardized and reproducible manner.
In this study, we utilized CFBE cells stably expressing CFTR missense variants to extend our under-
standing of  drug responses to CFTR bearing rare (minor allele frequency [MAF] < 1% in the CF population) 
missense variants. Our initial goal was to identify variants with either positive or less favorable responses to 
ivacaftor, lumacaftor, or ivacaftor-lumacaftor combination treatment to inform clinical applications. How-
ever, we discovered that response to the modulators was closely correlated with residual function of  the 
mutant forms of  CFTR for most variants expressed in CFBE cells. This observation was replicated with a 
different set of  missense variants expressed stably in FRT cells and was also apparent upon retrospective 
analysis of  previously published ivacaftor studies using another independent set of  FRT cells (18). Using 
these results, we devised a statistically valid approach to identify robust responders to ivacaftor and luma-
caftor based on the fold change in CFTR function. Furthermore, we showed that the combination of  the 
2 modulators produces a greater response for most missense variants, including high-response variants, 
than either drug alone. These observations, in concert with the recent demonstration that combinatorial 
treatment was efficacious for residual function variants (15), suggest that CFTR-targeted treatment may be 
appropriate for most individuals with CF carrying residual function missense variants.
Results
To assess the response of CFTR variants associated with a wide range of CF phenotypes to FDA-approved 
CFTR modulators, we studied 57 missense variants reported in individuals with CF using 2 cellular expres-
sion systems. Forty-three rare missense variants that were associated with a range of phenotypes measured 
by modest increases in sweat chloride concentration (40–90 mM) and/or pancreatic exocrine sufficiency (PS) 
prevalence greater than 50% were selected from the CFTR2 database (Table 1) and reported previously (22). 
Due to the moderate pancreatic disease, each variant was expected to allow residual CFTR function (23, 24) 
and was associated with less severe disease. To approximate the native environment of CFTR in the lung, the 
rare variants were studied in CBFE cells that are devoid of endogenous CFTR expression (21, 25). These CFBE 
cells have been used to generate cell lines expressing CFTR missense variants at a level comparable with prima-
ry human tissues in order to measure their effect on CFTR function and aid in interpretation of disease liability 
(22). A second set of 16 variants were expressed in FRT cells (Table 2), a cell type that has been employed to 
evaluate the response of CFTR to FDA-approved drugs (20), although the studies presented here were per-
formed on cell lines selected within a more narrow range of mRNA expression. These variants are generally 
more frequent in individuals with CF and are associated with more severe disease (60–106 mM and 2%–80% 
PS). Two variants, p.Arg334Trp (R334W) and p.Thr338Ile (T338I), were common to both groups, yielding 
a total study set of 57 unique variants. Variants F508del and G551D, which have been extensively studied 
previously, were also analyzed in both cell lines (3), bringing the total number of cell lines studied here to 63.
In each cell system, CFTR bearing each of  the missense variants was stably expressed from a single 
site of  integration, as previously described (18, 21, 22, 26). Residual CFTR function of  each missense 
variant in CFBE cells was measured as the magnitude of  forskolin-mediated (10 μM) cAMP-stimu-
lated current inhibited by CFTRinh-172 (inh-172; 10 μM), a widely used potent inhibitor of  CFTR (27), 
normalized to WT function based on mRNA expression level, as previously described (22), to calcu-
late a precise percent-WT function. CFTR function in FRT cells was measured as the magnitude of  
forskolin-mediated (5 μM) cAMP-stimulated current (with specificity confirmed by inh-172 [10 μM]) 
3insight.jci.org   https://doi.org/10.1172/jci.insight.121159
R E S E A R C H  A R T I C L E
compared with WT. All FRT cell lines selected for study expressed CFTR mRNA within a narrow 
range (0.5- to 1.5-fold) of  CFTR mRNA compared with a WT-expressing line generated by the same 
method (26). The 4 variants studied in both CFBE and FRT cells (R334W, T338I, F508del, and G551D) 
produced comparable levels of  CFTR function: F508del (CFBE, 0.5% WT; FRT, 1.6% WT); G551D 
(CFBE, 3.2% WT; FRT, 4.0% WT); R334W (CFBE, 2.0% WT; FRT, 3.9% WT); T338I (CFBE, 6.4% 
WT; FRT, 7.6% WT) (Table 1 and Table 2).
Table 1. Measurements of CFTR function and response to modulators in CFBE cells
 Variant HGVS cDNA Residual function (n) 10 μM 
Ivacaftor (n)
6 μM  
Lumacaftor (n)
10 μM ivacaftor 6 
μM lumacaftor (n)
P5L p.Pro5Leu c.14C>T 21.9 ± ± 2 (3) 25.9 ± 0.6 (3) 57.72 ± 0.6 (3) 62.2 ± 1.4 (3)
G27R p.Gly27Arg c.79G>A 0.9 ± 0.1 (3) 0.8 ± 0 (3) 5.14 ± 0.1 (3) 5.2 ± 0.3 (3)
W57G p.Trp57Gly c.169T>G 1.1 ± 0.1 (3) 1.3 ± 0.2 (3) 1.89 ± 0.1 (3) 2.5 ± 0.1 (3)
G91R p.Gly91Arg c.271G>A 1.6 ± 0.2 (3) 1.7 ± 0.1 (3) 14.29 ± 0.3 (3) 21.1 ± 0.2 (3)
Q98R p.Gln98Arg c.293A>G 4.5 ± 0.1 (3) 5.5 ± 0.2 (3) 14.32 ± 0.5 (3) 18.8 ± 0.9 (3)
P99L p.Pro99Leu c.296C>T 3.7 ± 0.1 (3) 5.1 ± 0.6 (3) 7 ± 0.5 (3) 10.2 ± 0.3 (3)
E116K p.Glu116Lys c.346G>A 6.9 ± 0.3 (3) 16.4 ± 0.5 (3) 11.60 ± 1.6 (3) 32.9 ± 0.5 (3)
R117L p.Arg117Leu c.350G>T 10.2 ± 2.5 (3) 17.8 ± 1.3 (3) 13.2 ± 1.5 (3) 25.4 ± 1.3 (3)
L138ins p.Leu138insLeu c.413_415dupTAC 1.6 ± 0.2 (3) 2.2 ± 0.2 (3) 16.1 ± 0.9 (3) 29.8 ± 1.1 (3)
H139R p.His139Arg c.416A>G 1.5 ± 0.5 (3) 2.3 ± 0.4 (3) 3.0 ± 0.3 (3) 3.3 ± 0.9 (3)
L145H p.Leu145His c.434T>A 5.6 ± 0.4 (3) 7.5 ± 0.4 (3) 51.5 ± 5.4 (3) 72.8 ± 3.6 (3)
L165S p.Leu165Ser c.494T>C 1.9 ± 0.1 (3) 1.7 ± 0.1 (3) 3.1 ± 0.2 (3) 4.8 ± 0.1 (3)
V232D p.Val232Asp c.695T>A 4.3 ± 0.4 (3) 5.5 ± 0.2 (3) 19.3 ± 2.3 (3) 30.5 ± 1.5 (3)
F311L p.Phe311Leu c.933C>G 5.1 ± 0.6 (3) 14.7 ± 0.4 (3) 7.3 ± 0.3 (0) 25.1 ± 0.7 (3)
R334W p.Arg334Trp c.1000C>T 2.0 ± 0.3 (13) 2.1 ± 0.2 (21) 2.2 ± 0.5 (8) 2.2 ± 0.3 (10)
R334L p.Arg334Leu c.1001G>T 2.5 ± 0.2 (3) 2.6 ± 0.1 (3) 3.5 ± 0.1 (0) 4.5 ± 0.3 (3)
R334Q p.Arg334Gln c.1001G>A 25.5 ± 1.4 (29) 34.2 ± 2.3 (30) 30.2 ± 2.1 (15) 40.9 ± 2.3 (15)
I336K p.Ile336Lys c.1007T>A 2.3 ± 0.3 (20) 3.2 ± 0.4 (24) 9.2 ± 0.9 (13) 20.1 ± 1.5 (26)
T338I p.Thr338Ile c.1013C>T 6.4 ± 0.3 (18) 14.2 ± 0.8 (18) 8.9 ± 0.8 (9) 20.3 ± 1.8 (9)
I340N p.Ile340Asn c.1019T>A 12.5 ± 0.9 (33) 16.5 ± 1.6 (21) 70 ± 10.4 (20) 79.8 ± 17.7 (14)
S341P p.Ser341Pro c.1021T>C 0.8 ± 0.1 (11) 1.5 ± 0.1 (13) 1.2 ± 0.1 (11) 2.9 ± 0.2 (13)
M348V p.Met348Val c.1042A>G 77.8 ± 7.4 (6) 138.8 ± 7.3 (6) 103.0 ± 17.3 (3) 124.2 ± 56.3 (6)
A349V p.Ala349Val c.1046C>T 45.5 ± 4.7 (13) 110.7 ± 11.2 (14) 94.9 ± 16.3 (7) 139.5 ± 32.3 (11)
L453S p.Leu453Ser c.1358T>C 3.4 ± 0.2 (3) 3.6 ± 0.3 (3) 6.7 ± 0.3 (3) 7.6 ± 0.1 (3)
V456A p.Val456Ala c.1367T>C 4.4 ± 0.4 (3) 6.9 ± 0 (3) 8.2 ± 0.7 (3) 11.5 ± 0.4 (3)
E474K p.Glu474Lys c.1420G>A 1.2 ± 0.1 (3) 1 ± 0.1 (3) 3.9 ± 0.5 (3) 5.9 ± 0.2 (3)
F508del p.Phe508del c.1521_1523del 0.5 ± 0.1 (15) 0.9 ± 0.2 (11) 1.8 ± 0.5 (10) 3.2 ± 0.7 (10)
D513G p.Asp513Gly c.1538A>G 7 ± 1.3 (3) 10.4 ± 0.3 (3) 12.9 ± 0.6 (3) 15.2 ± 0.9 (3)
G551D p.Gly551Asp c.1652G>A 3.2 ± 0.3 (38) 21.6 ± 1.8 (30) 4.9 ± 1.3 (14) 39.4 ± 4.2 (13)
Y563N p.Tyr563Asn c.1687T>A 0.6 ± 0 (3) 0.7 ± 0 (3) 0.9 ± 0 (3) 1 ± 0.1 (3)
P574H p.Pro574His c.1721C>A 4.3 ± 0.3 (3) 7.3 ± 0.3 (3) 11.5 ± 0.7 (3) 20.8 ± 0.5 (3)
H609R p.His609Arg c.1826A>G 1.9 ± 0.1 (3) 2.5 ± 0.1 (3) 2.8 ± 0.2 (3) 3.9 ± 0.1 (3)
A613T p.Ala613Thr c.1837G>A 2.7 ± 0.2 (3) 3.7 ± 0.1 (3) 6.1 ± 0.6 (3) 7.6 ± 0.7 (3)
G622D p.Gly622Asp c.1865G>A 18.8 ± 0.8 (3) 24.9 ± 0.8 (3) 41.7 ± 1.7 (3) 54.7 ± 0.8 (3)
D979V p.Asp979Val c.2936A>T 8.6 ± 1.8 (3) 19 ± 0.9 (3) 24.1 ± 5.9 (3) 72.4 ± 6.4 (3)
A1006E p.Ala1006Glu c.3017C>A 3.9 ± 0.4 (3) 4.8 ± 0.9 (3) 6.4 ± 1.4 (3) 10.2 ± 0.5 (3)
F1016S p.Phe1016Ser c.3047T>C 15.8 ± 1.5 (3) 24.7 ± 0.7 (3) 38.2 ± 4.7 (3) 55.4 ± 1.3 (3)
Y1032C p.Tyr1032Cys c.3095A>G 13 ± 1.6 (3) 14.2 ± 0.4 (3) 78.5 ± 8.3 (3) 76.4 ± 5.5 (3)
W1098C p.Trp1098Cys c.3294G>C 3.4 ± 0.3 (6) 4.1 ± 0.3 (6) 12.1 ± 0.7 (6) 19.1 ± 0.9 (6)
S1118F p.Ser1118Phe c.3353C>T 4.8 ± 0.5 (3) 8.6 ± 0.3 (3) 8.9 ± 0.2 (3) 18.3 ± 0.4 (3)
S1159F p.Ser1159Phe c.3476C>T 7.4 ± 1.3 (3) 43.8 ± 2.4 (3) 18.4 ± 3.8 (3) 59.5 ± 2.0 (3)
S1159P p.Ser1159Pro c.3475T>C 6.4 ± 0.5 (4) 29.3 ± 1.3 (4) 10.9 ± 1.6 (4) 42.2 ± 1.4 (4)
T1246I p.Thr1246Ile c.3737C>T 20 ± 2 (3) 52.9 ± 1.8 (3) 35.2 ± 1.8 (3) 74.7 ± 2.7 (3)
R1283M p.Arg1283Met c.3848G>T 10.3 ± 0.9 (3) 12.5 ± 0.7 (3) 12.1 ± 1 (3) 19.1 ± 0.7 (3)
L1335P p.Leu1335Pro c.4004T>C 2.6 ± 0.1 (3) 3.5 ± 0.1 (3) 3.2 ± 0.1 (3) 4.4 ± 0.1 (3)
HGVS, Human Genome Vairation Socienty nomenclature.
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CFTR missense variants expressed in CFBE cells were first tested for their response to 10 μM ivacaftor, 
a compound that is efficacious for variants that affect channel gating (5). G551D-CFTR in CFBE cells 
demonstrated a dose-dependent response to ivacaftor from 0.1–100 μM, similar to previously reported 
findings in FRT cells (5) (data not shown). Ivacaftor enhanced the forskolin-stimulated (10 μM) function 
of  many of  the variants tested in CFBE cells, regardless of  whether or not they were known to impair 
CFTR channel gating. Furthermore, the magnitude of  ivacaftor-enhanced CFTR activity correlated with 
the magnitude of  forskolin-activated CFTR activity (r = 0.96) (Figure 1A, Table 1, Supplemental Table 1; 
supplemental material available online with this article; https://doi.org/10.1172/jci.insight.121159DS1). 
Data were plotted on a logarithmic scale to visualize the entire functional range of  variants studied. To 
determine whether the observed correlation between ivacaftor response and residual function was cell-line 
independent, we analyzed the ivacaftor response of  16 CFTR variants and the G551D and F508del variants 
stably expressed in FRT cells. The response to ivacaftor also correlated with forskolin-activated CFTR 
function for all 18 variants expressed in FRT cells (r = 0.93) (Figure 1B, Table 2).
When data from CFBE and FRT studies were combined and evaluated as fold change over base-
line function, 4 cell lines (G551D expressed in both CFBE and FRT cells, p.Ser1159Phe [S1159F], and 
p.Ser1159Pro [S1159P] in CFBE cells) were found to be outliers (defined here as greater than 2 SD 
above the mean of  all variants tested) and labeled as high response. G551D is the prototype for highly 
responsive gating variants (5, 28), while S1159F and S1159P are 2 previously uncharacterized variants. 
When these outliers were removed, mean and SD were recalculated for all remaining data, and 4 outliers 
from this analysis (p.Phe311Leu [F311L], p.Met348Val [M348V], p.Thr1246Ile [T1246I], and p.Asn-
1303Lys [N1303K]) were separated and labeled as intermediate response; all other variants were labeled 
as modest-response variants, which accounted for the vast majority of  variants (Figure 1C). F311L, 
M348V, and T1246I are 3 previously untested variants, while N1303K is a variant of  particular interest. 
Single-channel studies revealed that, once delivered to the plasma membrane, N1303K-CFTR exhibited 
a severe gating defect characterized by infrequent brief  channel openings reminiscent of  the G551D vari-
ant (Supplemental Figure 1A) (29, 30). Ivacaftor (1 μM) modestly enhanced Po of  the N1303K variant by 
increasing the frequency and duration of  channel openings (Supplemental Figure 1, B–E). Taken togeth-
er, the short-circuit current (Isc) and single-channel studies indicate that ivacaftor can elicit an increase 
in N1303K function, although the extremely low residual function prevents a large absolute change in 
CFTR function after ivacaftor treatment.
Table 2. Measurements of CFTR function and response to modulators in FRT cells
Variant HGVS cDNA Residual  
function (n)
5 μM 
Ivacaftor (n)
3 μM  
Lumacaftor (n)
5 μM ivacaftor  
3 μM lumacaftor (n)
P67L p.Pro67Leu c.200C>T 10.7 ± 0.5 (3) 13.5 ± 0.7 (3) 62.1 ± 3.1 (3) 70.8 ± 4.8 (3)
G85E p.Gly85Glu c.245G>A 0.5 ± 0 (11) 0.5 ± 0 (11) 0.6 ± 0 (11) 0.7 ± 0.1 (11)
E92K p.Glu92Lys c.274G>A 1.3 ± 0.1 (6) 1.5 ± 0.1 (6) 14.2 ± 2.2 (6) 17.2 ± 2.6 (6)
R117H p.Arg117His c.350G>A 20.1 ± 2.4 (6) 38.3 ± 1.9 (6) 35.6 ± 2.6 (6) 62.9 ± 2.9 (6)
L206W p.Leu206Trp c.617T>G 7.0 ± 0.6 (6) 9.8 ± 0.9 (6) 60.1 ± 2.2 (6) 70.7 ± 2.3 (6)
R334W p.Arg334Trp c.1000C>T 3.9 ± 0.5 (5) 4.9 ± 0.5 (5) 5.1 ± 0.3 (5) 6.4 ± 0.3 (5)
T338I p.Thr338Ile c.1013C>T 7.6 ± 0.7 (6) 12 ± 0.5 (6) 13.7 ± 0.7 (6) 23.4 ± 1.1 (6)
R347P p.Arg347Pro c.1040G>C 1.0 ± 0.1 (9) 1.3 ± 0.1 (9) 4 ± 0.4 (9) 5.4 ± 0.4 (9)
A455E p.Ala455Glu c.1364C>A 5.6 ± 0.2 (3) 5.8 ± 0.2 (3) 14.8 ± 0.5 (3) 15.4 ± 0.2 (3)
S492F p.Ser492Phe c.1475C>T 1.7 ± 0.1 (3) 1.8 ± 0.1 (3) 6.6 ± 0.1 (3) 7.2 ± 0.2 (3)
F508del p.Phe508del c.1521_1523del 1.6 ± 0.1 (5) 2.1 ± 0.2 (5) 6.3 ± 0.4 (5) 9.6 ± 0.4 (5)
V520F p.Val520Phe c.1558G>T 0.5 ± 0 (5) 0.5 ± 0.1 (5) 1.4 ± 0 (6) 1.5 ± 0 (6)
G551D p.Gly551Asp c.1652G>A 4.0 ± 0.4 (5) 19.7 ± 0.7 (5) 9.9 ± 2 (6) 41.1 ± 0.8 (6)
R560T p.Arg560Thr c.1679G>C 0.1 ± 0 (7) 0.1 ± 0 (7) 0.1 ± 0 (9) 0.1 ± 0 (9)
A561E p.Ala561Glu c.1682C>A 0 ± 0 (6) 0 ± 0 (6) 0.1 ± 0 (6) 0.2 ± 0 (6)
L1077P p.Leu1077Pro c.3230T>C 0.9 ± 0 (6) 0.8 ± 0.1 (6) 4.2 ± 0.3 (6) 3.8 ± 0.3 (6)
M1101K p.Met1101Lys c.3302T>A 0.6 ± 0 (6) 0.5 ± 0 (6) 1.9 ± 0.1 (6) 1.7 ± 0 (6)
N1303K p.Asn1303Lys c.3909C>G 0.2 ± 0 (5) 0.5 ± 0 (5) 0.5 ± 0.1 (4) 1.5 ± 0 (4)
HGVS, Human Genome Vairation Socienty nomenclature. 
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We next evaluated previously published ivacaftor response data generated by 54 CFTR variants 
stably expressed in a separate FRT cell line established by Vertex Pharmaceuticals (noted here as 
FRT*) that overlapped with the 16 variants expressed in FRT cells in this study (18). Experimental 
conditions for measuring CFTR function were comparable with those used for the CFBE (21) and 
FRT (18) stable cell lines studied here. Correlation was evident for the variants studied in the FRT* 
cell lines (Figure 1D). Although drug doses differed between data sets, the CFBE and FRT data from 
this study were normalized to cells expressing WT CFTR treated with the same drug doses, allowing 
for comparison across cell types. When high- and intermediate-response variants were removed from 
analysis, the regression functions for all 3 independent studies had very similar slopes, intercepts, and 
high correlation (Figure 1E). These results indicate that ivacaftor increases CFTR function for most 
Figure 1. Ivacaftor response correlates with residual function. (A) Ivacaftor (10 μM) enhanced CFTR function compared with residual forskolin-stimulated (10 
μM) CFTR function for 45 variants expressed in CF bronchial epithelial (CFBE) cells. Each variant measured n ≥ 3 and was plotted as mean ± SEM on both axes. 
(B) Ivacaftor (5 μM) enhanced CFTR function compared with residual forskolin-stimulated (5 μM) CFTR function for 18 variants expressed in Fisher rat thyroid 
(FRT) cells. Each variant measured n ≥ 3 and was plotted as mean ± SEM on both axes. (C) Separation of variants based on their fold response to ivacaftor. 
Response of cell lines expressing G551D (CFBE), G551D (FRT), S1159F, and S1159P were designated as outliers by demonstrating fold response greater than 2 
SD beyond the mean fold response of all variants studied in CFBE and FRT cells and labeled as high-response variants. Intermediate-response variants were 
those that remained outliers when high-response variants were removed from the comparison. All remaining variants were classified as modest response. 
Lines through data points represent the mean value ± 1 SD for modest-response variants and mean of intermediate- and high-response variants. (D) Previ-
ously published data collected from FRT* cells (18, 19) of nongating variants plotted as in A and B. (E) Comparison of trend lines of modest-response variants 
identified in CFBE and FRT studies compared with nongating variants identified in FRT* cells. Correlation (r) values calculated using Pearson linear correlation.
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variants, regardless of  the specific molecular defect, as the variants studied confer a range of  defects 
in CFTR function.
Overall, the variants shared between studies yielded the same quality of  ivacaftor response across sys-
tems (i.e., high-response variants in one system were high-response variants in other systems). The fold 
increase in current following ivacaftor treatment was similar in both cell lines for F508del (1.76-fold in 
CFBE and 1.31-fold in FRT), G551D (6.81 -old in CFBE and 6.02-fold in FRT), R334W (1.03-fold in 
CFBE and 1.24-fold in FRT), and T338I (2.21-fold in CFBE and 1.58-fold in FRT).
Identification of  variants that allow CFTR to fold to a mature form but cause it to be poorly respon-
sive to ivacaftor could be informative for future drug design and optimization. To screen for potential poor 
responders, we plotted the published folding and chloride channel function effects of  54 CFTR variants 
(18, 19) (Figure 2A). We noted that a group of  variants, p.Ile336Lys (I336K), T338I, p.Ser341Pro (S341P), 
R334W, and p.Arg347Pro (R347P), located in transmembrane segment 6 (TM6) in membrane-spanning 
domain 1 (MSD1) of  CFTR permitted partial folding but severely disrupted channel function. TM6 is nota-
ble for its role in ion conductance (31), as it is predicted to line the channel pore by homology models and 
cryoelectron microscopy structures (32–37), measurements of  conductance properties (38–40), and evalua-
tion of  solvent accessibility (41–44). Based on these data, we hypothesized that variants that alter residues 
lining the channel pore might be resistant to CFTR potentiators, such as ivacaftor (18, 19). The 9 naturally 
occurring TM6 variants generated detectable mature (band C) CFTR, which suggested that each variant 
may allow at least partial CFTR maturation and residual CFTR function (Figure 2B; see complete uned-
ited blots in the supplemental material). Furthermore, the ivacaftor response of  TM6 variants increased as 
residual function increased from <1% WT to 78% WT, indicating that the 2 measurements are correlat-
ed (Figure 2C). The responses of  the TM6 variants to ivacaftor were modest and not different from the 
total set of  modest-response variants (Figure 2D). Furthermore, 2 TM6 variants, p.Arg334Gln (R334Q) 
and T338I, responded very similarly to a separate collection of  10 CFTR potentiator compounds obtained 
from CF Foundation Therapeutics (CFFT) CFTR Chemical Compound Program (Supplemental Figure 
2). Although TM6 variants had minimal residual CFTR function despite some of  them having efficient 
protein folding, a characteristic shared with gating variants, they are distinct in that they generated a modest 
response to potentiators, which was correlated with residual function similar to nongating missense variants.
Our next step was to test the response of  the missense variants to the CFTR corrector lumacaftor. 
Lumacaftor improves the biogenesis of  CFTR protein and has been primarily targeted to the common 
misfolding variant F508del (10). Importantly, lumacaftor has been reported to increase the function of  WT 
CFTR and a few missense variants (45, 46), as well as protein folding of  several other variants (47, 48). 
Accordingly, we tested the effect of  lumacaftor on the variants studied here. As with ivacaftor, the magni-
tude of  forskolin-stimulated CFTR function following incubation with 6 μM lumacaftor correlated with 
the forskolin-stimulated function of  each variant when incubated with an equal volume of  DMSO for the 
45 variants studied in CFBE cells (Figure 3A, Table 1). Correlation between residual function and luma-
caftor response was also observed in 18 variants expressed in FRT cell lines (Figure 3B, Table 2). Like the 
ivacaftor response, data from CFBE and FRT cells were combined and evaluated as fold response. Outliers 
for the lumacaftor response were determined by measuring 2 SD above the mean; p.Gly91Arg (G91R), 
p.Glu92Lys (E92K), p.Leu138insLeu (L138ins), p.Leu145His (L145H), and p.Leu206Trp (L206W) were 
designated as high-response variants, while p.Gly27Arg (G27R), p.Pro67Leu (P67L), p.Ile340Asn (I340N), 
and p.Tyr1032Cys (Y1032C) were designated as intermediate-response variants (Figure 3C). When high- 
and intermediate-response variants were removed from the analysis, the regression functions for CFBE and 
FRT modest-response variants demonstrated robust correlation (CFBE, r = 0.95; FRT, r = 0.98) with sim-
ilar slopes (Figure 3D). These results indicate that lumacaftor increases CFTR function for most variants, 
regardless of  the specific molecular defect, as the 59 variants studied confer a range of  folding defects in 
CFTR from mild to severe.
Lumacaftor has been shown to be effective at improving the protein processing of  variants located in 
MSD1 (47) and the intracellular loops (ICLs) (48). We were intrigued that 2 variants (I336K and I340N) 
located in TM6 within MSD1 demonstrated elevated responses to lumacaftor, which prompted further 
studies to verify and explain the responses of  these 2 TM6 variants. Lumacaftor increased the total amount 
of  mature CFTR protein expressed in stable CFBE cell lines for all variants (Figure 4A; see complete uned-
ited blots in the supplemental material), even though many of  them are naturally fully folded and processed 
(note the absence of  immature band B protein for most variants). We confirmed that this increase in protein 
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Figure 2. Variants located in the sixth transmembrane domain (TM6) show modest response to ivacaftor. (A) Plot of CFTR processing versus resid-
ual function for 54 variants previously expressed in FRT* cells (18) reveals heterogeneous response to 10 μM ivacaftor of partially or well-processed 
low–residual function missense variants (labeled). Filled green circles represent variants approved by FDA for ivacaftor treatment; G551D labeled in 
italics. (B) Western blot demonstrating that all TM6 variants produce mature C band CFTR protein when transiently expressed in HEK293 cells and 
representative Isc tracings of all TM6 variants stably expressed in CF bronchial epithelial (CFBE) cells demonstrating response to acute treatment with 
10 μM ivacaftor, recorded as area-corrected current (μA/cm2), over time, measured in minutes represented by tick marks in 1-minute intervals. Data are 
representative of n ≥ 3 for each variant. (C) Summary data for response of TM6 variants to acute treatment with 10 μM ivacaftor expressed as %WT 
function. Box plots divide the data by quartile, with the median value indicated by a horizontal line within the box and whiskers extended to minimum 
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quantity was not due to an increase in CFTR mRNA (Supplemental Figure 3). Given the variability in the 
fold response to lumacaftor (Figure 3, A and B), we tested up to 4 independently derived CFBE cell lines 
stably expressing each of  the 9 TM6 variants (Figure 4B). Multiple measurements of  the different clones 
of  TM6 variants demonstrated that the response to lumacaftor becomes more pronounced at higher levels 
of  residual function (Figure 4C). Notably, 2 TM6 variants (I336K and I340N) had significantly higher fold 
responses than the remaining 7 TM6 variants (Figure 4D). To explore whether the less responsive TM6 
variants respond to other CFTR correctors, we evaluated R334Q and T338I alongside the highly respon-
sive variant I340N using a series of  18 compounds obtained from the CFFT CFTR Chemical Compound 
Program. Only 2 compounds generated a greater response compared with the vehicle control (DMSO) for 
all 4 variants tested (C17 and C18), but neither approached the efficacy of  lumacaftor (Supplemental Fig-
ure 4). Since the TM6 variants are located on an α helix that spans the cell membrane, we speculated that 
the robust corrector activity might be related to the orientation of  the side chains of  the mutated residues 
relative to the proposed ion pore. Using the predicted α helical structure of  TM6 when CFTR is in its open 
conformation, the side chains of  residues R334, T338, S341, and M348 are predicted to reside in the chan-
nel pore, while I336, I340, and A349 are oriented such that they are embedded in either the protein or the 
lipid bilayer (Figure 4E). The results of  arginine scanning mutagenesis are consistent with this orientation 
for these residues (49), as are the cryo-EM structures of  CFTR in the ATP-bound state (37). Grouping of  
the responses of  TM6 variants by predicted orientation revealed a significant correlation with lumacaftor 
response (Figure 4F). These results suggest that amino acid substitutions at embedded residues in TM6 are 
particularly responsive to lumacaftor.
The combination therapy of  ivacaftor and lumacaftor (iva/lum) and ivacaftor paired with a differ-
ent corrector, tezacaftor, has demonstrated clinical benefit in individuals homozygous for F508del (13, 
14), and the latter combination is effective for individuals carrying 1 copy of  F508del and a variant 
that allows partial CFTR function (15). Based on these observations and the responses we observed 
with potentiator and corrector alone, we sought to determine the effects of  acute administration of  
ivacaftor after incubation (24 hours in CFBE cells or 48 hours in FRT cells) with lumacaftor (iva/
lum) on the 59 variants tested here. The response of  45 variants stably expressed in CFBE cells to iva/
lum correlated with CFTR function without modulators (Figure 5A). Results obtained from 18 vari-
ants expressed in FRT cells demonstrated a similar relationship (Figure 5B). High-response and inter-
mediate-response variants were separated from modest-response variants (Figure 5C); G91R, E92K, 
L138ins, L145H, and G551D (CFBE) were designated high-response variants, while L206W, I336K, 
G551D, and N1303K were designated as intermediate-response variants (note that absolute magnitude 
of  N1303K activity is quite low, although the relative modulator enhancement is substantial). Trend 
lines of  modest-response variants were again found to be very similar between CFBE and FRT cell 
lines (Figure 5D). Plotting of  all variants studied revealed robust correlation between forskolin-stimu-
lated CFTR function and iva/lum-enhanced CFTR function, illustrating that this relationship is inde-
pendent of  cell type and pathologic mechanism for each variant (Figure 5D).
To formally test whether iva/lum produces higher responses than either compound alone, we per-
formed a detailed analysis of  the 45 variants expressed in CFBE cells. Iva/lum combination treatment 
generated an equal or better response than either ivacaftor or lumacaftor for 30 of  33 variants that demon-
strated modest responses to iva/lum (Figure 6A). The variants that did not demonstrate significantly better 
function with iva/lum were p.His139Arg (H139R), R334W, and p.Asp513Gly (D513G), and these variants 
also did not demonstrate a significant response to either ivacaftor or lumacaftor. Five rare variants were 
found to have an intermediate or high response to ivacaftor; for these 5 variants, iva/lum combination 
treatment was greater or equal to either ivacaftor or lumacaftor treatment (Figure 6B). Six variants were 
intermediate- or high-response variants to lumacaftor treatment; for these 6 variants, iva/lum combination 
treatment was greater or equal to either ivacaftor or lumacaftor treatment (Figure 6C). Notably, the iva/lum 
combination was never worse than ivacaftor or lumacaftor alone. Out of  the 45 rare variants evaluated, the 
response to iva/lum was statistically significantly higher than forskolin-stimulated function for all variants 
except for H139R, R334W, and D513G.
and maximum values. (D) Fold response for acute treatment with 10 μM ivacaftor calculated over residual function (10 μM forskolin) of TM6 variants 
compared with modest-responsive variants identified in this study. Box plots divide the data by quartile, with the median value indicated by a horizon-
tal line within the box and whiskers extended to minimum and maximum values.
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Although the trends for modest-response variants are the results that apply to the majority of  variants 
and individuals with CF, the responses of  the intermediate- and high-response variants also warrant evalua-
tion. We compared the regression lines for modest-, intermediate-, and high-response variants for ivacaftor, 
lumacaftor, and iva/lum combination (Figure 7A). This analysis demonstrated that each response group 
yielded a steeper slope of  the regression for all 3 treatments. These steeper slopes suggest that higher-re-
sponse variants were distinguished by more effective modulator responses and were not the simple top end 
Figure 3. Lumacaftor response correlates with residual function. (A) Forskolin (10 μM) stimulated CFTR function of 45 missense variants expressed in CF 
bronchial epithelial (CFBE) cells treated for 24 hours with 6 μM lumacaftor compared with residual forskolin-stimulated (10 μM) CFTR function when incu-
bated for 24 hours with an equal volume of DMSO. Each variant was measured n ≥ 3 and plotted as mean ± SEM on both axes. (B) Forskolin-stimulated (5 
μM) CFTR function of 18 missense variants expressed in Fisher rat thyroid (FRT) cells treated for 48 hours with 3 μM lumacaftor compared with residual 
forskolin-stimulated (5 μM) CFTR function when incubated for 48 hours with an equal volume of DMSO. Each variant was measured n ≥ 3 and plotted as 
mean ± SEM on both axes. (C) Separation of variants based on their fold response to lumacaftor. Response of cell lines expressing G91R, E92K, L138ins, 
L145H, and L206W were designated as outliers by demonstrating fold response greater than 2 SD beyond the mean fold response of all variants studied 
in CFBE and FRT cells, and they are labeled as high-response variants. Intermediate-response variants were those that remained outliers when high-re-
sponse variants were removed from the comparison. All remaining variants were classified as modest response. Lines through data points represent the 
mean value ± 1 SD for modest-response variants and mean of intermediate- and high-response variants. (D) Comparison of best fit functions for variants 
expressed in CFBE and FRT cells, which demonstrated modest response to lumacaftor. Correlation (r) values calculated using Pearson linear correlation.
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Figure 4. Variants located in sixth transmembrane domain (TM6) with exceptional response to lumacaftor corresponds to embedded side chain 
orientation within channel pore. (A) Western blots of whole cell lysates from CF bronchial epithelial (CFBE) cell lines stably expressing TM6 variants 
show that lumacaftor increases the quantity of mature CFTR protein for all TM6 variants. Data are representative of n ≥ 3 for each variant. (B) Isc 
tracings of TM6 variants reveal that a subset of TM6 variants have an increased response to lumacaftor (lum) recorded as area corrected current (μA/
cm2), over time, measured in minutes represented by tick marks in 1-minute intervals. Data are representative of n ≥ 3 for each variant. (C) Luma-
caftor response of TM6 variants following 24-hour treatment with 6 μM lumacaftor or an equal volume of DMSO. Box plots divide the data by quar-
tile, with the median value indicated by a horizontal line within the box and whiskers extended to minimum and maximum values. (D) Lumacaftor 
response for each TM6 variant calculated as fold response over residual function compared with all modest-response variants identified in CFBE cells. 
Box plots divide the data by quartile, with the median value indicated by a horizontal line within the box and whiskers extended to minimum and 
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of  a normal distribution; we believe that the regressions would be parallel but elevated if  the latter were the 
case. When we compared across each tier of  response (modest, intermediate, and high) we found that the 
iva/lum combination generated the steepest regression for all 3 response levels (Figure 7B). Taken together, 
these results suggest that high-response variants are mechanistically distinct from modest-response variants 
and that iva/lum combination therapy is the best option for all variants, regardless of  whether they are 
modest- or high-response variants.
Discussion
The CFTR modulators ivacaftor and lumacaftor have been approved for treatment of  individuals with CF 
who carry a select set of  variants based on the specific mechanistic defects of  those variants. However, clini-
cal studies of  individuals with variants for which aberrant channel gating or folding is not the sole molecular 
defect, such as p.Pro67Leu (P67L) (50), p.Arg117His (R117H) (8), and other residual function variants (15, 
51), have all shown clinical benefit from ivacaftor in a mechanism-independent manner. Using a wide range 
of  variants expressed in 2 cell types, we show that residual CFTR function and drug response are highly cor-
related. Furthermore, we demonstrate that almost all tested variants generated higher currents in response to 
ivacaftor combined with lumacaftor than when treated with either compound alone. Following the common 
CF-causing variant F508del (52), missense variants represent the largest category of  remaining variants asso-
ciated with CF (3). Although the number of  missense variants studied here encompass a small fraction of  all 
missense variants reported in CFTR (57 of  >800), they represent a significant portion of  CF-causing alleles 
in the CF population. In total, the missense variants evaluated by this study represent 10% of  all alleles 
reported to CFTR2 and 13,062 of  15,082 individuals (87%) with at least 1 missense variant. Of  added signif-
icance to the CF community moving forward, our results predict that greater clinical benefit would likely be 
derived from combinatorial therapy for most individuals with CF who carry missense variants and are given 
modulator compounds. The utility of  this approach was recently demonstrated by a clinical trial employing 
modulator combinations (ivacaftor and tezacaftor) for individuals with residual CFTR function (15).
Heterologous expression of  CFTR mutants in FRT cells has been used extensively to test modulator 
response, particularly to ivacaftor (5, 10, 18, 19, 47). Based on the clinical efficacy and safety of  ivacaftor, 
the FDA elected to accept results of  CFTR testing in FRT cells as evidence to allow expansion of  iva-
caftor use without requiring clinical trials (20). This decision was reached based on the strong correlation 
between in vitro studies using FRT cells and clinical trials. Importantly, the results of  those studies agreed, 
despite using a nonhuman cell line expressing a single allele of  CFTR. This forward-thinking approach 
provides a path to treat every individual with CF who carries CFTR variants that are sufficiently responsive 
to modulators, and it provides a mechanism to address barriers of  formal clinical testing for CF individuals 
with ultra-rare or even private mutations. However, the possibility remains that certain variants or certain 
modulators will require CFTR to function in its native human airway cellular context. To this end, we 
tested variants in CFBE cells and compared our results with the FRT model that has been well established 
as a system for studying CFTR modulators. The CFBE and FRT cell lines used here expressed CFTR in a 
controlled manner by stable expression from a single locus that guarded against artefactual interpretation 
of  variants due to overexpression of  the allele. For example, the finding of  N1303K response to ivacaftor, 
if  taken on its own, could be suggestive of  clinical benefit, but the function in the expression-controlled 
FRT cell line demonstrates that the response is quite low and less likely to reach levels sufficient for clinical 
benefit. mRNA levels of  CFTR expressed in CFBE cells were also determined to be within normal physio-
logical limits of  native human tissues by RNA sequencing (RNA-seq) studies. Despite their differences, we 
believe that our efforts to maintain controlled expression allowed CFBE and FRT cells to generate highly 
consistent results across a wide range of  variants. The slopes and intercepts of  correlation between residual 
function and modulator responses were remarkably similar, suggesting that the observed relationships were 
highly likely to be due to CFTR rather than cell-specific factors.
Ivacaftor increased chloride currents of  G551D-CFTR by almost 7-fold in both cell lines, which is signifi-
cantly less than was observed in previous studies in FRT cells (18, 19), but it is more consistent with studies 
performed in primary cells (5) and other cellular contexts (6, 7). The rare variants S1159F and S1159P, located 
maximum values. (E) Predicted orientation of TM6 residues within the CFTR conductance pore when in the open conformation (32). (F) Lumacaftor 
response relative to residual function for TM6 variants when grouped based on predicted orientation within the pore. Box plots divide the data by 
quartile, with the median value indicated by a horizontal line within the box and whiskers extended to minimum and maximum values.
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prior to the second nucleotide-binding domain (NBD2) (53), also exhibited a high response to ivacaftor. Even 
after removing high-response variants from the analysis, a second set of  variants demonstrated a response to 
ivacaftor that was significantly elevated compared with the remaining variants. The high degree of  correlation 
between residual function and modulator response for modest-response variants (r = 0.94) suggests that base-
line function might predict ivacaftor response for all variants and not just the ones tested here. Although abso-
lute response to modulators may not be sufficient for very low–function variants to demonstrate significant 
Figure 5. Ivacaftor/lumacaftor (iva/lum) response correlates with residual function. (A) Ivacaftor (10 μM) enhanced CFTR function of 45 missense variants 
expressed in CFBE cells following for 24-hour incubation with 6 μM lumacaftor compared with residual forskolin-stimulated (10 μM) CFTR function when 
incubated for 24 hours with DMSO. Each variant was measured n ≥ 3 and plotted as mean ± SEM. (B) Ivacaftor (5 μM) enhanced CFTR function of 18 missense 
variants expressed in FRT cells following 24-hour incubation with 3 μM lumacaftor compared with residual forskolin-stimulated (5 μM) CFTR function when 
incubated for 24 hours with DMSO. Each variant was measured n ≥ 3 and plotted as mean ± SEM. (C) Separation of variants based on their fold response to 
lumacaftor. Response of cell lines expressing G91R, E92K, L138ins, L145H, and G551D (CFBE) were designated as outliers by demonstrating a fold response 
greater than 2 SD beyond the mean fold response of all variants studied in CFBE and FRT cells, and they are labeled as high-response variants. Interme-
diate-response variants were those that remained outliers when high-response variants were removed from the comparison. All remaining variants were 
classified as modest response. Lines through data points represent the mean value ± 1 SD for modest-response variants and mean of intermediate- and 
high-response variants. (D) Comparison of best fit functions for variants expressed in CFBE and FRT cells that demonstrated modest response to ivacaftor/
lumacaftor combination treatment. Correlation (r) values calculated using Pearson linear correlation.
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Figure 6. Summary of response of missense variants to CFTR modulators. (A) CFTR function for variants that were modest-response variants for 
ivacaftor and lumacaftor when treated with forskolin (baseline), ivacaftor, lumacaftor, or iva/lum combination. Error bars represent ± SEM.  
(B) Response to ivacaftor, lumacaftor, or ivacaftor/lumacaftor combination for variants designated as intermediate- or high-response to ivacaftor.  
(C) Response to ivacaftor, lumacaftor, or iva/lum combination for variants designated as intermediate or high response to lumacaftor.
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clinical benefit (i.e., crossing a 10% WT function disease threshold), evaluation by fold change could inform 
mechanism of action. Such mechanisms may be distinct from potentiator compounds that promote NBD 
dimerization (54) and guide rationale design of  more effective potentiators. In addition, differentiating vari-
ants that have exceptional responses will be important to establish accurate expectations for clinical outcomes.
The effect of  lumacaftor on CFTR-bearing missense variants has been less extensively studied than for 
ivacaftor, and the present study, to our knowledge, reports the largest collection of  variants tested for their 
response to lumacaftor. Lumacaftor was designed to target the common F508del variant, and we observed 
increased CFTR function in cell lines expressing F508del when treated with this compound. Although we 
were unable to fully recapitulate the magnitude of  effect previously published (10), we believe our findings 
of  a 4-fold increase in function from 0.5%–2% WT function are concordant with results from clinical studies 
demonstrating the ability of  lumacaftor to reduce sweat chloride in a dose-dependent manner up to a reduc-
tion of  6.6 mmol/l while being unable to significantly improve lung function (12) or other biomarkers of  
CFTR function (55). Correlation between residual CFTR function and lumacaftor response had previously 
Figure 7. Combination therapy yields larger response than monotherapy across all response tiers. (A) Comparison of response trends for ivacaftor 
(left), lumacaftor (middle), and ivacaftor/lumacaftor combination (right) of all variants studied in CF bronchial epithelial (CFBE) and Fisher rat thyroid 
(FRT) cell lines. (B) Comparison of response trends for all 3 treatment strategies for modest-response variants (left), intermediate-response variants 
(middle), and high-response variants (right).
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been observed in studies of  primary nasal epithelial cells bearing a small series of  missense variants (56). Fur-
thermore, in vitro and ex vivo studies of  missense variants demonstrate increased CFTR function following 
treatment with lumacaftor (46, 57). Thus, it is reasonable to expect that the observations in the CFBE and 
FRT cell lines will be relevant in vivo. We also identified missense variants that respond significantly better to 
lumacaftor than F508del (i.e., greater than 2 SD above the mean). These results suggest that individuals carry-
ing certain variants might respond better to lumacaftor than those who carry F508del. Although intermediate 
and high lumacaftor responses applied only to 9 variants, lumacaftor increased the CFTR function of  most 
variants tested, regardless of  the mechanism underlying their CFTR dysfunction. Thus, many individuals 
with CF who carry variants that allow protein production may also benefit from lumacaftor treatment. Given 
that tezacaftor is functionally similar to lumacaftor (58), we predict that the same benefit would be obtained 
when using this CFTR corrector, similar to what has been observed in studies of  primary cells (56).
The location of  the residues that confer high lumacaftor responses could inform the future development 
of  correctors. Of  the 6 variants that demonstrated robust responses to lumacaftor, 4 are located in the TMDs 
(E92K, L206W, I336K, and I340N), while the 2 variants with the highest responses are located in the ICLs: 
L138ins and L145H near the first ICL (ICL1) and Y1032C near the interface of  TM10 and ICL4. Recent 
evidence indicates that lumacaftor promotes interactions between ICL1 and NBD1 (59), as well as between 
ICL4 and NBD1 (48). Thus, the significant increases in current above baseline exhibited by CFTR bearing 
L138ins and L145H upon treatment with lumacaftor might be a consequence of  their locations. As luma-
caftor is thought to rescue CFTR function by improving protein folding and, hence, structure, we mapped 
the location of  all TM6 variants studied here onto models (32) and structures (36) of  the CFTR protein. 
I336K and I340N are found in TM6 at residues where cryo-EM structures (36, 37), homology modeling 
(32), and experimental evidence predicts that they are embedded (42, 43, 49), whereas all other variants, 
except for p.Ala349Val (A349V), are predicted to be oriented into the open channel pore. Although the 
lumacaftor response of  A349V was not found to be significantly different from all other missense variants, 
it was significantly higher than other TM6 variants (P < 0.05). These results indicate that missense variants 
that alter ion conductance by disruption of  the structure of  the pore are mechanistically distinct from those 
that more directly impede ion flow. Amelioration of  local folding defects imposed on the channel pore by 
variants such as I336K and I340N might underlie the prominent response of  these variants to lumacaftor.
Our extensive evaluation of  responses of  variants expressed in CFBE cells confirmed that the majority 
of  variants (42 of  45) demonstrated increased CFTR function when treated with iva/lum. Moreover, 26 of  
45 variants demonstrated greater responses to the combination than to ivacaftor or lumacaftor alone, while 
16 others showed an equal response to ivacaftor or lumacaftor that was higher than baseline function, and 
the combination was not found to be less effective than either individual modulator for any variant tested. 
Although some studies have observed antagonism between ivacaftor and lumacaftor for some genotypes 
(57, 60), we saw no evidence of  antagonistic effects between these compounds in either CFBE or FRT sys-
tems. The regression functions suggest that a minimum (~2% WT) amount of  residual function is required 
for ivacaftor action, likely due to the requirement of  well-folded and processed protein localized to the cell 
surface, while lumacaftor has no such requirement. The regression function for iva/lum combination treat-
ment removes the minimum function requirement for response, suggesting that lumacaftor action results 
in ivacaftor response. It is known that F508del results in multiple molecular defects that require correction 
(61, 62); therefore, combination therapy should be expected to be the most effective treatment for F508del 
(63) and other variants that have folding and activity defects. Combination therapy was also effective for 
variants with high responses to ivacaftor or lumacaftor, including G551D, indicating that individuals bear-
ing these variants could additionally benefit from combinatorial therapy.
Of significant note, the modest-response variants treated with the iva/lum combination crossed 10% WT 
function for variants with 3% baseline function. The threshold of  3% residual WT function as a differentiator 
of  predicted alleviation of  lung disease for combinatorial modulator therapy is important, as this level of  
CFTR activity also coincides with an approximate threshold for exocrine pancreatic sufficiency (64). Pancre-
atic sufficiency of  an individual with CF can be determined independently of  genetic testing, thus potentially 
removing hurdles to interpretation of  genetic variants — including incomplete genotyping, variants of  uncer-
tain significance, errors in genetic test reports, and extreme rarity of  missense variants, among other consid-
erations. Given the high correlation between baseline function and modulator response for modest-response 
variants (r = 0.94), residual function of  an individual may be a reasonable predictor of  drug response, which 
has been postulated previously based on studies of  primary cells of  a limited number of  genotypes (56).
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The exceptions to the modest responses to ivacaftor and lumacaftor are significant for individuals carrying 
those variants, as well as for informing mechanism and design of future CFTR modulators. Individuals who 
carry these highly responsive variants may be able to achieve significant levels of CFTR function and improved 
clinical outcomes, even if  their CFTR function without treatment is poor. Furthermore, understanding the 
mechanism underlying the strong response may inform development of more efficient versions of these modu-
lators, which can then confer larger responses to individuals carrying modest-response variants, as well. While 
these high-response variants might lead to significant improvements in clinical outcome, it is important to note 
different tiers of response when discussing therapeutic outcomes with patients. The specific level of function 
required to escape lung disease will vary to some degree among individuals due to modifier genes, environmen-
tal factors, and/or stochastic factors unique to each individual, as noted in studies of twins and siblings (65). 
The level of CFTR function required to demonstrate clinical benefit may in some cases be as low as 5%, as 
implied by RNA studies (66), or possibly as high as 25%, which was necessary to restore full ciliary function 
(67). Of note, the conservative threshold of 10% WT function is higher than what was achieved for combina-
torial treatment of F508del in both FRT and CFBE systems. This is important, since iva/lum has achieved 
clinical benefit and FDA approval for individuals who carry 2 copies of F508del (13). If  the response of mutant 
CFTR to newer derivatives and novel classes of modulators continues to correlate with residual function, it is 
possible that therapeutic response might be achieved in individuals with very minimal residual function.
Methods
Study design
Rare variants from the CFTR2 database that had moderate sweat chloride (40–90 mM) were selected for 
study in CFBE cells. The set of  moderate sweat variants were ranked in priority based on frequency within 
the CF population. Variants that had <10% WT function were selected to evaluate drug responses. Several 
of  the first cell lines made were also tested for drug response even if  their residual function was greater 
than 10% WT (D979V, Y1032C, G622D, and P5L). Missense variants from TM6 were based on previous 
studies (18, 31) (R334W, I336K, T338I, and S341P) or naturally occurring variants at positions of  interest 
(R334L, R334Q, I340N, M348V, and A349V). All TM6 variants were tested for drug response, regardless 
of  residual function. In total, variants were selected across a range of  clinical and molecular phenotypes to 
identify trends that might be useful for predicting the drug response of  novel missense variants identified in 
individuals without the need for in vitro testing. Functional testing was measured with a minimum of  n = 3 
for each cell line tested for each drug condition, as well as a minimum of  n = 3 for measurement of  CFTR 
expression by quantitative PCR (qPCR). Drug doses were assigned based on previous studies (5, 10, 18, 19, 
21) and compared with equivalent treatment with the drug vehicle (DMSO in all cases).
Generation of variant plasmids
CFBE cells. CFTR expression plasmids containing WT CFTR cDNA sequence used for generation of  
CFBE cell lines were provided by J. Rommens (University of  Toronto, Toronto, Ontario, Canada). Plasmid 
was modified to utilize the human EF1a promoter (21), to revert the V1475M polymorphism (21), and to 
include the V470M polymorphism for every variant known to carry it in cis. This plasmid was used as a 
template for generation of  variant CFTR alleles by site-directed mutagenesis. The complete CFTR cDNA 
was sequenced to guard against secondary mutations. Plasmids were confirmed to be competent for trans-
fection by transient transfection of  HEK293 cells and subsequent Western blotting to evaluate production 
of  protein (Supplemental Methods).
FRT cells. pcDNA5/FRT expression plasmid used for generation of  FRT cell lines was purchased from 
Thermo Fisher Scientific. CFTR cDNAs encoding variants were cloned in between NotI and XhoI restric-
tion sites of  the pcDNA5/FRT expression vector. All variants encoded the common V470M polymor-
phism except 3 (G85E, R347P, and M1101K), to reflect haplotypes commonly associated with these alleles.
Generation of stable cell lines
CFBE cells provided were by D. Gruenert (UCSF, San Francisco, California, USA). Cell lines were mod-
ified to include Flp recombinase integration site and mutate the large T antigen binding site, as previously 
described (21). Cells were transfected with CFTR variant plasmids in the presence of  the pOG44 recom-
binase plasmid. Cells were grown under hygromycin selection (100 μg/ml), and individual clones were 
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picked using cloning cylinders and were grown/expanded separately. CFTR expression level was confirmed 
by qPCR (Supplemental Methods).
Isogenic FRT cells were a gift from M. Welsh (University of  Iowa, Iowa City, Iowa, USA).
FRT cell lines were generated using the Flp-In system (Thermo Fisher Scientific) following previously 
published methods (18, 26). Multiple clones of  FRT cells expressing each variant were isolated, and CFTR 
mRNA levels were compared with an established WT CFTR line obtained by the same protocol. Cell lines 
with mRNA levels comparable to WT (within 0.5–1.5 fold) were selected for further study.
Measurement of CFTR function
CFBE. CFTR-mediated transepithelial Cl– currents were recorded using a [Cl–] gradient to magnify current 
size without permeabilizing the basolateral membrane as previously described (21, 46). Cells (1 × 105) were 
plated on Snapwell filters (Corning) and cultured for 6 days while submerged to a minimum transepithelial 
resistance (Rt) of  200 Ω × cm
2, while Isc measurements were performed with EasyMount Ussing chambers 
(Physiologic Instruments) using a chloride concentration gradient with high chloride buffer in the baso-
lateral chamber and low chloride buffer in the apical chamber (Supplemental Methods). Air was gently 
bubbled into the buffers to promote circulation. After cancelling voltage offsets, transepithelial voltage was 
clamped (referenced to the basolateral solution) at 0 mV and Isc recorded continuously. Once currents had 
stabilized, forskolin (Selleckchem) was administered to the basolateral chamber at a final concentration 
of  10 μM. Once stabilized at the maximal forskolin-stimulated current level, the inhibitor Inh-172 (Sel-
leckchem) was administered to the apical chamber at a final concentration of  10 μM. The contribution 
of  CFTR function to overall current was measured as the decline in current following administration of  
Inh-172 (ΔIsc). Assessment of  the functional consequence of  CFTR missense variants was performed by 
normalizing the ΔIsc based on mRNA quantity to quantify percent-WT function as described previously 
(22) (Supplemental Methods).
FRT. FRT cells (1.5 × 105) were seeded and cultured on Transwell permeable supports (Corning) for 5 
days to form well-polarized monolayers with a minimum Rt of  400 Ω × cm
2. Isc was evaluated in the pres-
ence of  basolateral to apical chloride concentration gradient (Supplemental Methods) with an EasyMount 
Ussing Chamber System (Physiologic Instruments) and Acquire and Analyze software. Once current stabi-
lized, 100 μM amiloride was applied to both the apical and basolateral sides to inhibit the epithelial sodium 
channel ENaC. To activate the CFTR-specific chloride current, 5 μM forskolin (MilliporeSigma) was add-
ed to both sides. Inh-172 (10 μM; MilliporeSigma) was applied to the apical side to inhibit CFTR-mediat-
ed current. The process for determining percent-WT function in FRT cells was similar to that previously 
reported (68) but used a narrow range of  mRNA expression (Supplemental Methods).
Western blots of stable cell lines
Lysate (100 μg of  total) was collected from CFBE cells. Blots were probed with anti-CFTR mouse monoclo-
nal antibody 596, provided by Cystic Fibrosis Foundation Therapeutics (J. Riordan, University of  North Car-
olina, Chapel Hill, North Carolina, USA) at a concentration of  1:1,000 and secondary anti-mouse antibody 
(GE Healthcare, catalog NA931V) at a concentration of  1:100,000. The sodium potassium (Na+/K+) ATPase 
was used as a loading control for all blots; primary antibody was rabbit monoclonal antibody (Abcam, catalog 
ab76020, clone EP1845Y) at a concentration of  1:50,000 and secondary anti-rabbit (GE Healthcare, cata-
log NA934V) antibody concentration was 1:200,000. All blots were imaged using ECL Prime reagent (GE 
Healthcare) and x-ray film.
Potentiator testing
CFBE cells were prepared for Isc measurements as described above. Following stabilization of  the for-
skolin-stimulated current, ivacaftor (Selleckchem) was administered to the apical chamber at a final 
concentration of  10 μM. Potentiators provided by the CFFT CFTR Chemical Compound Program 
(R. Bridges, Rosalind Franklin University of  Medicine and Science, North Chicago, Illinois, USA) 
were also administered into the apical chambers at concentrations corresponding to their published 
half-maximal effective concentration (EC50) values (69–73). Inh-172 was applied to measure the CFTR 
portion of  the current. The effects of  potentiators were measured as the Inh-172–inhibited portion (ΔIsc) 
of  the current when stimulated by forskolin and then enhanced by the potentiator compared with the 
ΔIsc when stimulated by forskolin only.
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FRT cells were prepared for Isc measurements as described above. Following stabilization of  the forsko-
lin-stimulated current, 5 μM ivacaftor (Selleckchem) was applied to the apical side only. Finally, 10 μM inh-
172 (MilliporeSigma) was applied to the apical side to inhibit CFTR-mediated current. Ivacaftor-enhanced 
function was measured as the ΔIsc of  the ivacaftor-enhanced forskolin-activated current and compared with 
ΔIsc when stimulated by forskolin only.
Corrector testing
CFBE cells were grown in the presence of  corrector compound or equivalent volume of  DMSO for 24 
hours. Lumacaftor (Selleckchem) was administered at a final concentration of  6 μM, while corrector com-
pounds provided by the CFFT CFTR Chemical Compound Program (R. Bridges, Rosalind Franklin Uni-
versity of  Medicine and Science) were tested at concentrations corresponding to their EC50 values (74–79). 
The effects of  correctors on CFTR function were evaluated by Isc comparison of  forskolin-stimulated 
CFTR currents of  cells treated with each compound compared with the DMSO-treated negative control. 
To evaluate the effect of  lumacaftor on protein processing, total protein lysates were collected from stable 
cells after 24-hour incubation with 3 μM lumacaftor or an equivalent volume of  DMSO, and Western blots 
were performed as described above.
FRT cells were prepared for Isc measurements as described above. Forty-eight hours prior to assay, cells 
were treated with 3 μM lumacaftor (Selleckchem) or DMSO from both apical and basolateral surfaces of  the 
epithelia. The effects of  correctors on CFTR function were evaluated by Isc comparison of  forskolin-stimu-
lated CFTR currents of  cells treated with each compound compared with the DMSO-treated negative control.
Structural analysis
Cryo-EM structures and homology models of  the open conformation of  CFTR (32, 36, 37) were used to map 
the position and orientation of  the residues studied here using Pymol software and publicly available Protein 
Data Bank (PDB) files (5W81,5UAK, 2ONJ, and 2HYD).
Statistics
Designation of  modulator response outliers was performed by designating those responses with fold chang-
es greater than 2 SD above the mean as high-response variants. High-response variants were removed from 
the data set, and outliers from the remaining data set (greater than 2 SD above the mean) were designated 
as intermediate-response variants; all other responses were designated as modest-response variants. Results 
are presented as mean values ± SEM for scatter plots and bar plots. Box plots divide the data by quartile, 
with the median value indicated by a horizontal line within the box and whiskers extended to minimum 
and maximum values. Correlations were calculated by Pearson linear correlations. Statistical significance 
was calculated by Student’s unpaired 2 tailed t tests. Differences were considered statistically significant 
when P < 0.05. Complete individual data sets for each cell line are available in Supplemental Table 1.
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